NEW CFO TO KARO BIO
Karo Bio has recruited Erika Johnson as new CFO for the company. Erika is presently CFO for Affibody AB.
Erika Johnson (born 1970) has a long and broad experience from the financial and business sector. After graduating from the Stockholm School of Economics (1993) Erika worked for a 9 year period (1993)-02) at Enskilda Securities. At Enskilda Erika was involved in a number of transactions, like IPOs, new share issues and acquisitions. Erika also participated in building a small cap business with focus on growth companies within biotech, IT and telecom. In the biotech industry Erika has been CFO for Global Genomics (2002-05) and for Affibody AB.
“We are happy that Erika has accepted to become CFO at Karo Bio”, says Per Olof Wallström, President of Karo Bio. “We wish her very welcome and I am convinced that she in a most positive way will contribute to our future development”.
KARO BIO AB
For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer
Telephone: +46 8 608 60 20
Per Otteskog, Senior Vice President
Telephone: +46 8 608 60 18
Leif Carlsson, Chief Financial Officer
Telephone: +46 8 608 60 73.
Facts about Karo Bio
Karo Bio is a drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals with focus on metabolic diseases. Karo Bio has three clinical and four preclinical projects.
The company has expanded from being a drug discovery company by adding in-house preclinical and clinical development resources and competence for development of drugs to treat metabolic diseases. The company has a strong project portfolio with innovative molecules that primarily targets diseases such as diabetes, atherosclerosis and dislipidemia. In all of these areas there are significant market opportunities and a growing need for new pharmaceuticals with new mechanisms of action.
In addition to the proprietary projects Karo Bio has two strategic collaborations with international pharmaceutical companies and one biotech collaboration for development of innovative therapies for the treatment of common diseases.
Karo Bio is listed on the Stockholm Stock Exchange since 1998 (Reuters: KARO.ST).
This press release is also available online at: www.karobio.com and www.waymaker.net.